AAL,BRIEF-TWU-IAM reaches interim deal with American AirlinesBRIEF-American Airlines says new pay rates to increase pre-tax operating costs by about $75 mln in Q3 - SEC filingAmerican Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.   American Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  * Estimate new pay rates will increase pre-tax operating costs by about $75 million in Q3 2016 and $120 million in Q4 - SEC filing  Source text - http://bit.ly/2aAcwmn Further company coverage:American Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.    BRIEF-American Airlines says new pay rates to increase pre-tax operating costs by about $75 mln in Q3 - SEC filingAmerican Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.   American Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  * Estimate new pay rates will increase pre-tax operating costs by about $75 million in Q3 2016 and $120 million in Q4 - SEC filing  Source text - http://bit.ly/2aAcwmn Further company coverage:American Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.   * TWU-IAM union says reached interim deal with American Airlines to provide about 30,000 ground workers about 22 percent wage hikes, retirement improvements  Source text for Eikon:BRIEF-American Airlines says new pay rates to increase pre-tax operating costs by about $75 mln in Q3 - SEC filingAmerican Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.   American Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  * Estimate new pay rates will increase pre-tax operating costs by about $75 million in Q3 2016 and $120 million in Q4 - SEC filing  Source text - http://bit.ly/2aAcwmn Further company coverage:American Airlines reaches interim deal to hike ground staff wagesUPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.  UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately. Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effectively immediately.UPDATE 1-American Airlines reaches interim deal to hike ground staff wages Aug 5 American Airlines Group Inc said it had reached an interim agreement with a labor union to raise wages for about 30,000 of its ground staff, effective immediately.    
ANTM,UPDATE 2-Cognizant's forecast weak as Brexit weighs on clientsCognizant's forecast weak as Brexit weighs on clientsUPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.   UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  IT services provider Cognizant Technology Solutions Corp  forecast current-quarter revenue below analysts' estimates, citing the impact of Brexit vote on its clients from the financial services industry.UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.    Cognizant's forecast weak as Brexit weighs on clientsUPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.   UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  IT services provider Cognizant Technology Solutions Corp  forecast current-quarter revenue below analysts' estimates, citing the impact of Brexit vote on its clients from the financial services industry.UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.   * Shares recoup early losses   (Adds President comment, details, background, updates shares)Cognizant's forecast weak as Brexit weighs on clientsUPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.   UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  IT services provider Cognizant Technology Solutions Corp  forecast current-quarter revenue below analysts' estimates, citing the impact of Brexit vote on its clients from the financial services industry.UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.    
T,BRIEF-At&T; Inc. Announces offers to exchange twenty-one series of notes for new notes due 2048 and 2049 and cash, as applicable Aug 5 At&T; Inc. Announces Offers To Exchange Twenty 
BHI,BRIEF-Baker Hughes reports July 2016 rig counts * Worldwide rig count for July 2016 was 1,481, up 74 from 1,407 counted in June 2016, and down 686 from 2,167 counted in July 2015. 
BAC,MOVES-MOVES-BAML hires Devalier as head of Japan economicsU.S. asks appeals court to reconsider Bank of America rulingU.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.  U.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis. NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.U.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.   U.S. asks appeals court to reconsider Bank of America rulingU.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.  U.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis. NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.U.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.  LONDON, Aug 5 (IFR) - Bank of America Merrill Lynch said Izumi Devalier is to join the US bank from HSBC as head of Japan Economics.U.S. asks appeals court to reconsider Bank of America rulingU.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.  U.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis. NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.U.S. asks appeals court to reconsider Bank of America ruling NEW YORK, Aug 5 The U.S. government has asked a federal appeals court to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis.   
BMY,Bristol-Myers' Opdivo fails late-stage study in lung cancer patientsBRIEF-Bristol-Myers' Opdivo fails late-stage study in patients with lung cancerAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.    AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   * Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of Opdivo (nivolumab) in treatment-naïve patients with advanced non-small cell lung cancerAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.     BRIEF-Bristol-Myers' Opdivo fails late-stage study in patients with lung cancerAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.    AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   * Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of Opdivo (nivolumab) in treatment-naïve patients with advanced non-small cell lung cancerAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.    Aug 5 Bristol-Myers Squibb Co said its blockbuster immunotherapy, Opdivo, failed to improve survival in previously untreated patients with a form of lung cancer, without their disease progressing, in a late-stage study.BRIEF-Bristol-Myers' Opdivo fails late-stage study in patients with lung cancerAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.    AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   * Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of Opdivo (nivolumab) in treatment-naïve patients with advanced non-small cell lung cancerAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesBRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. * Moody's: Bristol's lung cancer trial result a major setbackUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.     
CNP,BRIEF-Centerpoint Energy reports qtrly loss per share of $0.01BRIEF-CenterPoint Energy reaffirms FY guidance of $1.12 - $1.20 per share - SEC Filing * Reaffirms full-year guidance of $1.12 - $1.20 per diluted share - SEC Filing  BRIEF-CenterPoint Energy reaffirms FY guidance of $1.12 - $1.20 per share - SEC Filing * Reaffirms full-year guidance of $1.12 - $1.20 per diluted share - SEC Filing * Q2 revenue view $1.67 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:BRIEF-CenterPoint Energy reaffirms FY guidance of $1.12 - $1.20 per share - SEC Filing * Reaffirms full-year guidance of $1.12 - $1.20 per diluted share - SEC Filing  
CI,UPDATE 2-Cognizant's forecast weak as Brexit weighs on clients * Shares recoup early losses   (Adds President comment, details, background, updates shares) 
C,Citigroup beats $800 mln appeal by onetime billionaireUPDATE 1-Citigroup beats $800 mln appeal by one-time billionaireCitigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.  Citigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold. NEW YORK, Aug 5 A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.Citigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.   UPDATE 1-Citigroup beats $800 mln appeal by one-time billionaireCitigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.  Citigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold. NEW YORK, Aug 5 A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.Citigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.  NEW YORK, Aug 5 A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.UPDATE 1-Citigroup beats $800 mln appeal by one-time billionaireCitigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.  Citigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold. NEW YORK, Aug 5 A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.Citigroup beats $800 mln appeal by one-time billionaire NEW YORK A federal appeals court rejected a one-time Florida billionaire's bid to revive his $800 million lawsuit accusing Citigroup Inc of fraudulently hiding its exposure to subprime and other toxic mortgages, inducing him to hold on to shares he otherwise would have sold.   
CTSH,Cognizant revenue jumps nearly 9.2 percent Aug 5 IT services provider Cognizant Technology Solutions Corp's quarterly revenue rose 9.2 percent, driven by strong demand for its cloud services from healthcare and finance clients. 
KHC,Kraft Heinz eyes product quality as consumer tastes changeUPDATE 3-Berkshire profit up 25 percent as insurance helps, BNSF weighs Aug 5 Berkshire Hathaway Inc on Friday said its second-quarter profit rose 25 percent, helped by improvement in insurance underwriting, investment gains and the purchase of Precision Castparts Corp, Warren Buffett's largest acquisition.  UPDATE 3-Berkshire profit up 25 percent as insurance helps, BNSF weighs Aug 5 Berkshire Hathaway Inc on Friday said its second-quarter profit rose 25 percent, helped by improvement in insurance underwriting, investment gains and the purchase of Precision Castparts Corp, Warren Buffett's largest acquisition. Kraft Heinz Co , the maker of Velveeta cheese, Heinz ketchup and Oscar Mayer meats, is reviewing all its product categories to improve quality, an executive said on Thursday, as it works to win over customers whose tastes have shifted away from processed foods.UPDATE 3-Berkshire profit up 25 percent as insurance helps, BNSF weighs Aug 5 Berkshire Hathaway Inc on Friday said its second-quarter profit rose 25 percent, helped by improvement in insurance underwriting, investment gains and the purchase of Precision Castparts Corp, Warren Buffett's largest acquisition.  
MRK,BRIEF-Merck announces U.S. FDA filing acceptance of new drug application (NDA) for mk-1293AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  Aug 5 Merck Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For MkAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woesUPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.  UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine. LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine.   
MON,German stocks - Factors to watch on August 5 FRANKFURT, Aug 5 The following are some of the factors that may move German stocks on Friday: 
NFLX,Alibaba says it is not making an investment in Netflix SAN FRANCISCO, Aug 5 Alibaba Group Holding Inc  is not making an investment in Netflix Inc, Alibaba spokesman Bob Christie told Reuters on Friday. 
RF,BRIEF-Regions Financial names Rick Ulmer CEO of Regions InsuranceRegions Financial, DoJ agree amount to settle mortgage loan probeREFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday.  REFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday. Aug 5 Regions Financial Corp said it had agreed with the U.S. Justice Department the amount to be paid to settle an investigation related to mortgage loans.REFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday.   Regions Financial, DoJ agree amount to settle mortgage loan probeREFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday.  REFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday. Aug 5 Regions Financial Corp said it had agreed with the U.S. Justice Department the amount to be paid to settle an investigation related to mortgage loans.REFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday.  * Regions Financial names Rick Ulmer president and CEO of Regions Insurance  Source text for Eikon:  Further company coverage:Regions Financial, DoJ agree amount to settle mortgage loan probeREFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday.  REFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday. Aug 5 Regions Financial Corp said it had agreed with the U.S. Justice Department the amount to be paid to settle an investigation related to mortgage loans.REFILE-UPDATE 1-Regions Financial to settle U.S. probe of mortgage practices Aug 5 Regions Financial Corp has agreed on a payment to settle a U.S. Justice Department investigation of its mortgage loans, the bank said in a filing on Friday.   
UNH,UPDATE 3-U.S. challenge to Anthem-Cigna deal gets new judgeU.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case. WASHINGTON, Aug 5 The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc from buying Cigna Corp, who had been seen as favorable for the deal, has relinquished the case.U.S. challenge to Anthem-Cigna deal gets new judge WASHINGTON The judge overseeing the U.S. government's bid to stop health insurer Anthem Inc  from buying Cigna Corp , who had been seen as favorable for the deal, has relinquished the case.  
UPS,REFILE-Spanish competition watchdog probes FedEx, UPS, DHL, Royal Mail Aug 5 Spain's competition watchdog said it was investigating logistics companies including United Parcel Service Inc, FedEx Corp, Deutsche Post's DHL Group and Britain's Royal Mail Plc for possible anti-competitive practices. 
WY,BRIEF-Weyerhaeuser Q2 earnings per share $0.21 * Q2 earnings per share view $0.22 -- Thomson Reuters I/B/E/S 
